前列腺癌诊断标志物研究进展  

New research of diagnostic biomarkers of prostate cancer

作　　者：洪西 刘利杰[1] 俞建军[1,2] HONG Xi;LIU Lijie;YU Jianjun(Department of Urology,Shanghai.Jiao Tong University Affiliated Sixth People's Hospital, Shanghai,200233,China;Department of Urology,Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus)

机构地区：[1]上海交通大学附属第六人民医院泌尿外科,上海200233 [2]上海市奉贤区中心医院泌尿外科

出　　处：《临床泌尿外科杂志》2018年第12期1012-1015,共4页Journal of Clinical Urology

摘　　要：前列腺癌是严重危害男性健康的肿瘤,有较高的恶性倾向,在我国发病率逐年上升。前列腺癌患者生存和预后的关键在于早期诊断与有效的治疗。目前临床以前列腺特异性抗原(PSA)及穿刺活检为主要诊断方法,但存在特异度不高、过度穿刺活检等问题。寻找高特异度、高敏感度的前列腺癌诊断标志物是目前研究热点。近年研究发现了长链非编码RNA(lncRNA)、TMPRSS2:ERG融合基因等许多新的肿瘤诊断标志物,对PSA及前列腺癌基因3(PCA3)等诊断标志物的研究也有新的进展,本文针对前列腺癌诊断标志物研究进展作一综述。Prostate cancer is a malignant tumor which seriously endangers the health of men,and it has a malignant tendency.The incidence of prostate cancer is increasing yearly in China.Early diagnosis and active treatment are the key to survival and prognosis of prostate cancer patients.At present,prostate specific antigen(PSA)and needle biopsy are the main diagnostic methods,but the specificity is not high,which leads to unnecessary biopsy and so on.Searching for high specificity and high sensitivity prostate cancer diagnostic biomarkers is the focus of current research.Recent studies have found the long chain non-coding RNA,TMPRSS2:ERG fusion gene and many new tumor diagnostic biomarkers and new progress has also been made in the study of PSA and PCA3.This article will focus on research progress of prostate cancer diagnostic biomarkers.

关 键 词：前列腺癌 诊断 标志物 前列腺特异性抗原 表观遗传 

分 类 号：R737.25[医药卫生—肿瘤]